Chimeric Antigen Receptor (CAR) therapy for multiple myeloma

Elotuzumab Therapy for Relapsed or Refractory Multiple Myeloma

(2015) Sagar Lonial et al.   NEW ENGLAND JOURNAL OF MEDICINE

Targeting CD38 with Daratumumab Monotherapy in Multiple Myeloma

(2015) Henk M. Lokhorst et al.   NEW ENGLAND JOURNAL OF MEDICINE

Remote control of therapeutic T cells through a small molecule-gated chimeric receptor

(2015) C.-Y. Wu et al.   SCIENCE

Novel anti-B-cell maturation antigen antibody-drug conjugate (GSK2857916) selectively induces killing of multiple myeloma

(2014) Y.-T. Tai et al.   BLOOD

ICOS-based chimeric antigen receptors program bipolar TH17/TH1 cells

(2014) S. Guedan et al.   BLOOD

Curing myeloma at last: defining criteria and providing the evidence

(2014) B. Barlogie et al.   BLOOD

Current concepts in the diagnosis and management of cytokine release syndrome

(2014) D. W. Lee et al.   BLOOD

Long-term survival after allogeneic stem cell transplantation for advanced stage multiple myeloma

(2014) Marie-Christiane Vekemans et al.   BRITISH JOURNAL OF HAEMATOLOGY

Accumulation of Memory Precursor CD8 T Cells in Regressing Tumors following Combination Therapy with Vaccine and Anti-PD-1 Antibody

(2014) L. Karyampudi et al.   CANCER RESEARCH

Genetic Modification of T Cells Redirected toward CS1 Enhances Eradication of Myeloma Cells

(2014) J. Chu et al.   CLINICAL CANCER RESEARCH

Molecular Pathways: The Immunogenic Effects of Platinum-Based Chemotherapeutics

(2014) S. V. Hato et al.   CLINICAL CANCER RESEARCH

SAR650984, A Novel Humanized CD38-Targeting Antibody, Demonstrates Potent Antitumor Activity in Models of Multiple Myeloma and Other CD38+ Hematologic Malignancies

(2014) J. Deckert et al.   CLINICAL CANCER RESEARCH

Serglycin Proteoglycan Is Required for Multiple Myeloma Cell Adhesion,in VivoGrowth, and Vascularization

(2014) Anurag Purushothaman et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Blockade of CD200 in the Presence or Absence of Antibody Effector Function: Implications for Anti-CD200 Therapy

(2014) A. Kretz-Rommel et al.   JOURNAL OF IMMUNOLOGY

Generation of a new therapeutic peptide that depletes myeloid-derived suppressor cells in tumor-bearing mice

(2014) Hong Qin et al.   NATURE MEDICINE

Chimeric Antigen Receptor T Cells for Sustained Remissions in Leukemia

(2014) Shannon L. Maude et al.   NEW ENGLAND JOURNAL OF MEDICINE

Immune regulatory effects of panobinostat in patients with Hodgkin lymphoma through modulation of serum cytokine levels and T-cell PD1 expression

(2014) Y Oki et al.   Blood Cancer Journal

Immunological Dysregulation in Multiple Myeloma Microenvironment

(2014) Alessandra Romano et al.   Biomed Research International

Targeting Immune Suppression with PDE5 Inhibition in End-Stage Multiple Myeloma

(2014) K. A. Noonan et al.   Cancer Immunology Research

The inducible caspase-9 suicide gene system as a “safety switch” to limit on-target, off-tumor toxicities of chimeric antigen receptor T cells

(2014) Tessa Gargett et al.   Frontiers in Pharmacology

CD44v6-targeted T cells mediate potent antitumor effects against acute myeloid leukemia and multiple myeloma

(2013) M. Casucci et al.   BLOOD

PANORAMA 2: panobinostat in combination with bortezomib and dexamethasone in patients with relapsed and bortezomib-refractory myeloma

(2013) P. G. Richardson et al.   BLOOD

Tumor-promoting immune-suppressive myeloid-derived suppressor cells in the multiple myeloma microenvironment in humans

(2013) G. T. Gorgun et al.   BLOOD

Expression profiling of TCR-engineered T cells demonstrates overexpression of multiple inhibitory receptors in persisting lymphocytes

(2013) D. Abate-Daga et al.   BLOOD

Phase I, multicentre, dose-escalation trial of monotherapy with milatuzumab (humanized anti-CD74 monoclonal antibody) in relapsed or refractory multiple myeloma

(2013) Jonathan L. Kaufman et al.   BRITISH JOURNAL OF HAEMATOLOGY

Doxorubicin Eliminates Myeloid-Derived Suppressor Cells and Enhances the Efficacy of Adoptive T-Cell Transfer in Breast Cancer

(2013) D. Alizadeh et al.   CANCER RESEARCH

Inhibition of CSF-1 Receptor Improves the Antitumor Efficacy of Adoptive Cell Transfer Immunotherapy

(2013) S. Mok et al.   CANCER RESEARCH

Accessory Cells of the Microenvironment Protect Multiple Myeloma from T-Cell Cytotoxicity through Cell Adhesion-Mediated Immune Resistance

(2013) S. J. de Haart et al.   CLINICAL CANCER RESEARCH

Adoptive T-cell Transfer Therapy and Oncogene-Targeted Therapy for Melanoma: The Search for Synergy

(2013) M. L. M. Kwong et al.   CLINICAL CANCER RESEARCH

Adoptive Transfer of Tumor-Infiltrating Lymphocytes in Patients with Metastatic Melanoma: Intent-to-Treat Analysis and Efficacy after Failure to Prior Immunotherapies

(2013) M. J. Besser et al.   CLINICAL CANCER RESEARCH

A Phase I Study of an Agonist CD40 Monoclonal Antibody (CP-870,893) in Combination with Gemcitabine in Patients with Advanced Pancreatic Ductal Adenocarcinoma

(2013) G. L. Beatty et al.   CLINICAL CANCER RESEARCH

B-cell Maturation Antigen Is a Promising Target for Adoptive T-cell Therapy of Multiple Myeloma

(2013) R. O. Carpenter et al.   CLINICAL CANCER RESEARCH

Interleukin-7 Mediates Selective Expansion of Tumor-redirected Cytotoxic T Lymphocytes (CTLs) without Enhancement of Regulatory T-cell Inhibition

(2013) S. K. Perna et al.   CLINICAL CANCER RESEARCH

Anti-PD-1 Antibody Therapy Potently Enhances the Eradication of Established Tumors By Gene-Modified T Cells

(2013) L. B. John et al.   CLINICAL CANCER RESEARCH

Minimal Residual Disease Assessed by Multiparameter Flow Cytometry in Multiple Myeloma: Impact on Outcome in the Medical Research Council Myeloma IX Study

(2013) Andy C. Rawstron et al.   JOURNAL OF CLINICAL ONCOLOGY

Continued improvement in survival in multiple myeloma: changes in early mortality and outcomes in older patients

(2013) S K Kumar et al.   LEUKEMIA

Coinhibitory molecule PD-1 as a potential target for the immunotherapy of multiple myeloma

(2013) D Atanackovic et al.   LEUKEMIA

CS1-specific chimeric antigen receptor (CAR)-engineered natural killer cells enhance in vitro and in vivo antitumor activity against human multiple myeloma

(2013) J Chu et al.   LEUKEMIA

Transfection of chimeric anti-CD138 gene enhances natural killer cell activation and killing of multiple myeloma cells

(2013) Hua Jiang et al.   Molecular Oncology

Inhibition of p300 impairs Foxp3+ T regulatory cell function and promotes antitumor immunity

(2013) Yujie Liu et al.   NATURE MEDICINE

Combination with a Defucosylated Anti-HM1.24 Monoclonal Antibody plus Lenalidomide Induces Marked ADCC against Myeloma Cells and Their Progenitors

(2013) Takeshi Harada et al.   PLoS One

PD-1- and CTLA-4-Based Inhibitory Chimeric Antigen Receptors (iCARs) Divert Off-Target Immunotherapy Responses

(2013) V. D. Fedorov et al.   Science Translational Medicine

Long-term survival in multiple myeloma is associated with a distinct immunological profile, which includes proliferative cytotoxic T-cell clones and a favourable Treg/Th17 balance

(2013) C Bryant et al.   Blood Cancer Journal

Clinical drug resistance linked to interconvertible phenotypic and functional states of tumor-propagating cells in multiple myeloma

(2012) A. Chaidos et al.   BLOOD

CD86+ or HLA-G+ can be transferred via trogocytosis from myeloma cells to T cells and are associated with poor prognosis

(2012) R. Brown et al.   BLOOD

Serum B-cell maturation antigen is elevated in multiple myeloma and correlates with disease status and survival

(2012) Eric Sanchez et al.   BRITISH JOURNAL OF HAEMATOLOGY

A phase 1 study of lucatumumab, a fully human anti-CD40 antagonist monoclonal antibody administered intravenously to patients with relapsed or refractory multiple myeloma

(2012) William Bensinger et al.   BRITISH JOURNAL OF HAEMATOLOGY

High-Avidity T Cells Are Preferentially Tolerized in the Tumor Microenvironment

(2012) Z. Zhu et al.   CANCER RESEARCH

Cellular Constituents of Immune Escape within the Tumor Microenvironment

(2012) S. P. Kerkar et al.   CANCER RESEARCH

Indoleamine 2,3-dioxygenase 1 (IDO1) activity correlates with immune system abnormalities in multiple myeloma

(2012) Giuseppina Bonanno et al.   Journal of Translational Medicine

Clinical significance of CD81 expression by clonal plasma cells in high-risk smoldering and symptomatic multiple myeloma patients

(2012) B Paiva et al.   LEUKEMIA

Anti-CD47 antibodies promote phagocytosis and inhibit the growth of human myeloma cells

(2012) D Kim et al.   LEUKEMIA

Marrow stromal cells induce B7-H1 expression on myeloma cells, generating aggressive characteristics in multiple myeloma

(2012) H Tamura et al.   LEUKEMIA

Phase I study of the anti-CD40 humanized monoclonal antibody lucatumumab (HCD122) in relapsed chronic lymphocytic leukemia

(2012) John C. Byrd et al.   LEUKEMIA & LYMPHOMA

FcRL5 as a Target of Antibody-Drug Conjugates for the Treatment of Multiple Myeloma

(2012) K. Elkins et al.   MOLECULAR CANCER THERAPEUTICS

Combinatorial antigen recognition with balanced signaling promotes selective tumor eradication by engineered T cells

(2012) Christopher C Kloss et al.   NATURE BIOTECHNOLOGY

B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor-transduced T cells

(2011) J. N. Kochenderfer et al.   BLOOD

A phase 1, multicenter, open-label, dose escalation study of elotuzumab in patients with advanced multiple myeloma

(2011) J. A. Zonder et al.   BLOOD

Surface molecule CD229 as a novel target for the diagnosis and treatment of multiple myeloma

(2011) D. Atanackovic et al.   HAEMATOLOGICA

Phase I study of the anti insulin-like growth factor 1 receptor (IGF-1R) monoclonal antibody, AVE1642, as single agent and in combination with bortezomib in patients with relapsed multiple myeloma

(2011) P Moreau et al.   LEUKEMIA

Multiple Myeloma

(2011) Antonio Palumbo et al.   NEW ENGLAND JOURNAL OF MEDICINE

The PD-1/PD-L1 axis modulates the natural killer cell versus multiple myeloma effect: a therapeutic target for CT-011, a novel monoclonal anti-PD-1 antibody

(2010) D. M. Benson et al.   BLOOD

A phase I multidose study of dacetuzumab (SGN-40; humanized anti-CD40 monoclonal antibody) in patients with multiple myeloma

(2010) M. Hussein et al.   HAEMATOLOGICA

International Myeloma Working Group Consensus Statement Regarding the Current Status of Allogeneic Stem-Cell Transplantation for Multiple Myeloma

(2010) Henk Lokhorst et al.   JOURNAL OF CLINICAL ONCOLOGY

Daratumumab, a Novel Therapeutic Human CD38 Monoclonal Antibody, Induces Killing of Multiple Myeloma and Other Hematological Tumors

(2010) M. de Weers et al.   JOURNAL OF IMMUNOLOGY

Tetraspanin-induced death of myeloma cell lines is autophagic and involves increased UPR signalling

(2009) V Zismanov et al.   BRITISH JOURNAL OF CANCER

Functional B7.2 and B7-H2 Molecules on Myeloma Cells Are Associated with a Growth Advantage

(2009) T. Yamashita et al.   CLINICAL CANCER RESEARCH

The Monoclonal Antibody nBT062 Conjugated to Cytotoxic Maytansinoids Has Selective Cytotoxicity Against CD138-Positive Multiple Myeloma Cells In vitro and In vivo

(2009) H. Ikeda et al.   CLINICAL CANCER RESEARCH

CD81 protein is expressed at high levels in normal germinal center B cells and in subtypes of human lymphomas

(2009) Robert F. Luo et al.   HUMAN PATHOLOGY

Activated T–cell-mediated Immunotherapy With a Chimeric Receptor Against CD38 in B-cell Non-Hodgkin Lymphoma

(2009) Keichiro Mihara et al.   JOURNAL OF IMMUNOTHERAPY

Multiple myeloma

(2009) Marc S Raab et al.   LANCET

Combinatorial efficacy of anti-CS1 monoclonal antibody elotuzumab (HuLuc63) and bortezomib against multiple myeloma

(2009) F. van Rhee et al.   MOLECULAR CANCER THERAPEUTICS

CS1, a Potential New Therapeutic Antibody Target for the Treatment of Multiple Myeloma

(2008) E. D. Hsi et al.   CLINICAL CANCER RESEARCH

Adoptive Cell Therapy for Patients With Metastatic Melanoma: Evaluation of Intensive Myeloablative Chemoradiation Preparative Regimens

(2008) Mark E. Dudley et al.   JOURNAL OF CLINICAL ONCOLOGY

Anti-CS1 humanized monoclonal antibody HuLuc63 inhibits myeloma cell adhesion and induces antibody-dependent cellular cytotoxicity in the bone marrow milieu

(2007) Y.-T. Tai et al.   BLOOD